人类免疫缺陷病毒感染/艾滋病患者并发非酒精性脂肪性肝病的影响因素分析

肝脏 ›› 2026, Vol. 31 ›› Issue (3): 428-432.

人类免疫缺陷病毒感染/艾滋病患者并发非酒精性脂肪性肝病的影响因素分析

王永素, 张林, 牛卫理

458000 鹤壁鹤壁市第三人民医院感染科

收稿日期:2025-03-28 出版日期:2026-03-31 发布日期:2026-05-19
通讯作者: 张林,Email:923657539@qq.com
基金资助:
河南省医学科技攻关计划联合共建项目(LHGJ20230866)

Analysis of non-alcoholic fatty liver disease and its influencing factors in HIV/AIDS patients

WANG Yong-su, ZHANG Lin, NIU Wei-li

Department of Infectious Diseases, the Third People′s Hospital of Hebi City, Hebi 458000, China

Received:2025-03-28 Online:2026-03-31 Published:2026-05-19
Contact: ZHANG Lin, Email: 923657539@qq.com

摘要/Abstract

摘要： 目的了解接受抗逆转录病毒治疗(ART)的人类免疫缺陷病毒感染或艾滋病(HIV/AIDS)并发非酒精性脂肪性肝病(NAFLD)及其影响因素,为HIV/AIDS并发NAFLD患者的防治提供参考。方法选取2023年10月至2024年4月于鹤壁市第三人民医院就诊并正在接受ART治疗的76例HIV/AIDS患者作为研究对象,收集相关资料,进行统计学分析。结果 76例HIV/AIDS患者中,并发NAFLD的占比为53.95%(41/76)。HIV/AIDS并发NAFLD患者的体质指数(BMI)≥24 kg/m²占比为82.9%、目前服用含依非韦伦(EFV)方案且≥60个月占比为51.2％、TG异常占比为73.2%、任一血脂指标异常占比为75.6%、血糖异常占比为61.0%、体脂含量为29.51%±4.98%,均高于未并发NAFLD的患者(分别为37.1%、22.9%、37.1%、51.4%、31.4%和24.83%±6.14%),差异有统计学意义,P<0.05。经多因素logistic回归分析发现,BMI≥24 kg/m²、目前服用含EFV方案且≥60个月及TG异常可能为并发NAFLD的影响因素,P<0.05,差异具有统计学意义。结论接受ART的HIV/AIDS患者NAFLD并发率高,BMI≥24 kg/m²、目前服用含EFV方案且≥60个月和TG异常可能是并发NAFLD的影响因素。

关键词: 人类免疫缺陷病毒感染/艾滋病, 非酒精性脂肪性肝病, 影响因素

Abstract: Objective To understand the non-alcoholic fatty liver disease ( NAFLD ) and its influencing factors in HIV/AIDS patients receiving antiretroviral therapy ( ART ), and to provide reference for the prevention and treatment of NAFLD in HIV/AIDS patients. Methods A total of 76 HIV/AIDS patients who were treated with ART in the Third People′s Hospital of Hebi City from October 2023 to April 2024 were selected as the research objects. Relevant data were collected and statistically analyzed. Results The proportion of NAFLD in 76 HIV/AIDS patients was 53.95%(41/76). The proportion of BMI ≥ 24 kg/m² (82.9%), the proportion of taking EFV regimen and ≥ 60 months(51.2%), the proportion of abnormal TG (73.2%), the proportion of abnormal blood lipid index ( 75.6 % ), the proportion of abnormal blood glucose ( 61.0% ) and body fat content ( 29.51% ± 4.98% ) in patients with NAFLD were higher than those in patients without NAFLD ( 37.1%, 22.9%, 37.1%, 51.4%, 31.4% and 24.83%± 6.14%, respectively ). The difference was statistically significant (P<0.05). Multivariate logistic regression analysis showed that BMI≥24 kg/m², taking EFV regimen and ≥ 60 months and abnormal TG may be influencing factors of NAFLD, and the difference were statistically significant (P<0.05). Conclusion The proportion of NAFLD in HIV / AIDS patients receiving ART is high. BMI ≥ 24 kg/m², taking EFV regimen and ≥ 60 months, and abnormal TG were influencing factors of NAFLD.

Key words: HIV/AIDS, Non-alcoholic fatty liver disease, Influencing factor

王永素, 张林, 牛卫理. 人类免疫缺陷病毒感染/艾滋病患者并发非酒精性脂肪性肝病的影响因素分析[J]. 肝脏, 2026, 31(3): 428-432.

WANG Yong-su, ZHANG Lin, NIU Wei-li. Analysis of non-alcoholic fatty liver disease and its influencing factors in HIV/AIDS patients[J]. Chinese Hepatolgy, 2026, 31(3): 428-432.

/ 推荐

参考文献

[1] Paula A A, Schechter M, Tuboi S H, et al. Continuous increase of cardiovascular diseases, diabetes, and non-HIV related cancers as causes of death in HIV-infected individuals in Brazil: an analysis of nationwide data[J]. PLoS One, 2014,9(4): e94636.
[2] Duarte M, Tien P, Ma Y, et al. Controlled attenuation parameter accurately detects liver steatosis in people with HIV[J]. AIDS, 2022, 36(15):2147-2152.
[3] 范建高,徐小元,南月敏,等.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J].实用肝脏病杂志,2024,27(4):494-510.
[4] 郭萌,郭琦,张峰.超声瞬时弹性成像检测受控衰减参数评估非酒精性脂肪性肝病患者肝脂肪变程度价值研究[J].实用肝脏病杂志,2024,27(2):189-192.
[5] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心.中国艾滋病诊疗指南(2021年版)[J].中国艾滋病性病,2021,27(11):1182-1201.
[6] 孙婉璐, 孙长贵, 陈光榆,等.肝脏受控衰减参数与代谢综合征关系的临床研究[J].中华肝脏病杂志,2017,25 (2):128-133.
[7] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志,2023,38(3):237-271.
[8] 肖江,李鑫,韩宁,等.HAART后艾滋病病人脂肪肝临床特点分析[J].中国艾滋病性病,2011,17(2):118-121.
[9] 中华医学会内分泌学分会.非酒精性脂肪肝肝病与相关代谢紊乱诊疗共识(第二版)[J].临床肝胆病杂志,2018,34(10):2103-2108.
[10] 刘俊,龚涛,牟治青,等.喻建华教授诊治艾滋病合并非酒精性脂肪肝临床经验[J],中医医结合肝病杂志,2023,33(5):447-449.
[11] Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons[J]. J Acquir Immune Defic Syndr, 2009,50(5):464-473.
[12] 舒筠然,李俊琪,刘琼,等.非酒精性脂肪性肝病的流行病学和危险因素分析[J].临床肝胆病杂志,2019,35(9):2085-2090.
[13] 刘敏,石峰,吴玉珊,等.以依非韦伦为基础的抗病毒治疗方案对成人人类免疫缺陷病毒感染者血脂影响的临床研究[J].中国感染与化疗杂志,2019,19(4):366-370.
[14] 何溪,李凌华,朱媛媛,等.三种常见抗病毒方案对成人HIV/AIDS初治患者血脂的影响[J].广州医科大学,2019,47(3):51-56.
[15] 刘敏,石峰,刘倩,等. 依非韦伦和洛匹那韦/利托那韦对成人艾滋病患者血脂水平影响的对比研究[J]. 中华传染病杂志,2021,39(3):175-177.
[16] Kotlyarov S, Bulgakov A. Lipid ,metabolism disorders in the comorbid course of nonalcoholic fatty liver disease and chronic obstructive pulmonary disease[J]. Cells, 2021,10(11):2978.
[17] 李智慧.HIV/AIDS患者接受抗病毒治疗后血脂、血糖变化及影响因素分析[D].大理大学.2023.
[18] 李鑫,肖江,宋淑静,等.瘦素、脂联素和胰岛素敏感指数与艾滋病HAART后非酒精性脂肪肝相关性分析[J].胃肠病学和肝病学杂志,2012,21(9):851-854.